Development of small molecule viral sensitizers to boost vaccine manufacturing

基于病毒的疫苗是社会上预防致命人类疾病最成功的药物。天花、小儿麻痹症、麻疹、腮腺炎和风疹等疾病已基本从实施广泛疫苗接种计划的人群中消除。所有疫苗的一个共同特征是它们必须被工程化或选择为具有减毒的生长特征，以确保在人类中可接受的安全性。虽然减弱病毒疫苗阻断细胞先天免疫应答的能力产生了一种非常安全的产品，但它也削弱了用于工业生产的细胞系中病毒的生长，减少了疫苗的及时交付。在2009年H1N1疫苗接种计划期间经历的急性疫苗供应短缺强调了

Virus-based vaccines are society's most successful pharmaceuticals for the prevention of deadly human diseases. Diseases like smallpox, polio, measles, mumps and rubella have been essentially eliminated from human populations where widespread vaccination programs have been implemented. One characteristic common to all vaccines is that they must be engineered or selected to have attenuated growth characteristics in order to ensure an acceptable safety profile in humans. While attenuation of the ability of a viral vaccine to block cellular innate immune responses creates an extremely safe product, it also impairs the growth of the virus in cell lines used for industrial manufacturing, decreasing the timely delivery of vaccines. The acute vaccine supply shortages experienced during the 2009 H1N1 vaccination program underscore the need for